Abstract
The present industry update covers the period 1-31 March 2018. Sources of information included company press releases, regulatory and patent agencies notices and various news websites. A number of companies reported positive early-stage clinical trial results for therapeutic candidates enabled by different delivery strategies including Cerenis Therapeutics Inc. and Enteris. March also saw the announcement of some significant collaborations; Bluebird Bio and Celgene announced plans for a collaboration with a view to developing a novel CAR-T therapy, and Windtree Therapeutics Inc. and Eleison Pharmaceuticals Inc. agreed to form a partnership to facilitate the delivery of inhaled liquid cisplatin. InMed Pharmaceuticals and OncoSec Medical Inc., companies engaged at preclinical evaluation of their delivery technologies, also announced publications this month on the development of their platforms.
| Original language | English |
|---|---|
| Pages (from-to) | 505-510 |
| Number of pages | 6 |
| Journal | Therapeutic Delivery |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2018 |
| Externally published | Yes |
Keywords
- CAR-T
- competitor intelligence
- emerging technologies
- ocular drug delivery